ACADIA Pharmaceuticals Inc. - Common Stock (ACAD)

ACADIA Pharmaceuticals stock jumped 26.4% Friday afternoon. Shares gained following a favorable court ruling.

Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

ACADIA PHARMACEUTICALS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:ACAD showcases decent financial health and profitability, coupled with an attractive price.

ACADIA PHARMACEUTICALS INC was identified as an affordable growth stock. NASDAQ:ACAD is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.

Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.

ACADIA Pharmaceuticals shares are trading lower by 4.6% during Tuesday's session. The company appointed Catherine Owen Adams as CEO.

Cramer gives his take on E.l.f Beauty, Acadia Pharmaceuticals, B&G Foods, Lucid, SoFi, Dell, Johnson & Johnson, UWM and Symbotic.

Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations.